AMRN - Amarin Corporation PLC logo

Amarin Corporation PLC

AMRN

Amarin Corporation develops and commercializes therapeutics for cardiovascular diseases, focusing on VASCEPA, a prescription omega-3 fatty acid used to lower triglyceride levels in patients. It sells primarily through wholesalers and pharmacies globally.

โš•๏ธ Healthcare NASDAQ Listed 1993 $ USD
$1,000 invested 30 years ago โ†’$1today

Score Overview

1 Year
Score
Net Growth30.09%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-13.71%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.6
Net Growth-450.92%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-68.39%
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Score
Net Growth68.59%
Net Trend70%
Net Income Consistency
Rev Growth41.72%
Rev Trend40%
Revenue Consistency
20 Years
Score4.0
Net Growth-0.75%
Net Trend60%
Net Income Consistency
Rev Growth368x
Rev Trend57%
Revenue Consistency
30 Years
Score
Net Growth-73.86%
Net Trend53%
Net Income Consistency
Rev Growth8x
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-30x
Net Trend55%
Net Income Consistency
Rev Growth12x
Rev Trend52%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Amarin Corporation PLC has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • AMRN

2004: 98.9% ยท 2018: 54.3% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 13.25โ€”
1 Year2025-09-26
$ 16.00-17.19%
5 Years2021-09-28
$ 105.00-87.38%
10 Years2016-09-28
$ 64.80-79.55%
20 Years2006-09-28
$ 530.00-97.50%
30 Years1996-09-26
$ 14.5K-99.91%
All Time1993-04-01
$ 12K-99.89%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 184M-$ 27M
2025$ 213M-$ 38M$ 302M
2024$ 228M-$ 82M$ 294M
2023$ 306M-$ 59M$ 320M
2022$ 369M-$ 105M$ 309M
2021$ 583M$ 7M$ 454M
2020$ 614M-$ 18M$ 500M
2019$ 429M-$ 22M$ 644M
2018$ 229M-$ 116M$ 249M
2017$ 181M-$ 67M$ 73M
2016$ 130M-$ 86M$ 98M
2015$ 81M-$ 115M$ 106M
2014$ 54M-$ 56M$ 119M
2013$ 26M-$ 166M$ 191M
2012-$ 179M$ 260M
2011-$ 69M$ 116M
2010-$ 249M$ 31M
2009-$ 59M$ 52M
2008-$ 20M$ 11M
2007$ 7M-$ 38M$ 18M
2006$ 500K-$ 26M$ 36M
2005$ 500K-$ 20M$ 33M
2004$ 1M$ 3M$ 10M
2003$ 7M-$ 19M$ 2M
2002$ 65M-$ 37M$ 24M
2001$ 4M-$ 4M$ 30M
2000$ 15M$ 2M$ 2M
1999$ 11M$ 4M$ 1M
1998$ 10M-$ 28M$ 800K
1997$ 24M-$ 7M$ 5M
1996$ 21M-$ 15M$ 4M
1995$ 29M$ 4M$ 12M
1994$ 18M$ 2M
IPO1993$ 14M$ 900K$ 9M
AMRN - Amarin Corporation PLC logo

Amarin Corporation PLC fundamental performance

Between 2015 and 2025, revenue grew from $ 81M to $ 213M and net income went from -$ 115M to -$ 38M. Revenue increased in 4 of those 10 years; net income in 7.

Between 2005 and 2025, revenue grew from $ 500K to $ 213M and net income went from -$ 20M to -$ 38M. Revenue increased in 11 of those 20 years; net income in 12.

Amarin Corporation PLC currently holds a 20-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Membership

Continue AMRNโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies